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dipyridamole stress echocardiography versus perfusion scintigra-
phy. In contrast to Fragasso et al., Astarita et al. used a “state-of-
the-art” atropine protocol, and they in fact observed that dipyrid-
amole sensitivity was raised to 88%. Stress echocardiography
protocols have evolved rapidly in recent years. When the diagnosis
is the target, atropine coadministration should be used. When
prognostic stratification is the reason for testing, a high dose
without atropine, even in hypertensive patients (6), provides
excellent stratification (7).
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REPLY
We are grateful to Dr. Varga for his comments on our report (1),
because his letter gives us the opportunity to further clarify our
opinion. Like others (2), in the past, we have used dipyridamole for
the diagnosis of coronary artery disease, but we (3) have been unable
to reproduce the diagnostic accuracy reported by some groups.
Interestingly enough, the near totality of these data comes from a
single institution. In our study, we decided not to use atropine to
assess the intrinsic strength of the individual stressors. The sensitivi-
ties and specificities for perfusion scintigraphy, dipyridamole and
dobutamine echocardiography were 98% and 36%, 61% and 91%,
88% and 80% respectively. As a consequence, accuracy, which takes in
account both sensitivity and specificity, was not significantly different
between the three tests, although dobutamine appeared to perform
better (84%) than dipyridamole (74%) and scintigraphy (71%). Fur-
thermore, in patients with one-vessel disease, the performance of
dipyridamole was very poor, with a sensitivity of 31%. We do not
think that the addition of atropine could have increased this figure to
an acceptable level, especially if we take into account that, in this
subgroup, the sensitivities of dobutamine and scintigraphy were 85%
and 95%, respectively. Indeed, we believe that such differences are
enough to justify our statement that dobutamine echocardiography (as
well as rest/stress myocardial perfusion scintigraphy) are better than
dipyridamole echocardiography in these patients. We cannot afford
the risk of missing so many patients with coronary artery disease in
such a high-risk group. In addition, this statement is also justified by
pathophysiologic considerations. Dobutamine increases oxygen de-
mand by increasing contractility, heart rate and systolic blood pres-
sure. These features make dobutamine an ideal stressor in hyperten-
sion. In contrast, dipyridamole produces coronary vasodilation, with
little “myocardial stress,” as defined by changes in the rate–pressure
product and a lesser likelihood of causing myocardial ischemia. This
is why dipyridamole yields high sensitivities when used with scintig-
raphy, where perfusion abnormalities are thought to represent areas of
altered blood flow rather than areas of ischemia; however, this is also
why its sensitivity is low when used with echocardiography.
Surely, the addition of atropine improves sensitivity, but it also
leaves misdiagnosed a large proportion of patients with single-
vessel disease. Furthermore, although dipyridamole is considered a
safe test, most patients experience considerable side effects. Ami-
nophylline is administered at the end of the test, and, when
atropine has also been given, sustained sinus tachycardia usually
ensues, causing discomfort and making the duration of the test as
long as dobutamine testing. On the basis of these considerations,
we think that dobutamine provides the best performance for the
diagnosis of coronary artery disease in hypertensive patients (and
beyond). Our feeling (allowed in a letter!) is that most cardiologists
around the world share the same opinion.
Gabriele Fragasso, MD
Division of Cardiology
Istituto Scientifico San Raffaele
Via Olgettina 60
Milano 20132, Italy
E-mail: fragasso.gabriele@hsr.it
PII S0735-1097(00)00660-4
REFERENCES
1. Fragasso G, Lu C, Dabrowski P, Pagnotta P, Sheiban I, Chierchia SL.
Comparison of stress/rest myocardial perfusion tomography, dipyrida-
mole and dobutamine stress echocardiography for the detection of
coronary disease in hypertensive patients with chest pain and positive
exercise test. J Am Coll Cardiol 1999;34:441–7.
2. Dagianti A, Penco M, Agati L, et al. Stress echocardiography: com-
parison of exercise, dipyridamole and dobutamine in detecting and
predicting the extent of coronary artery disease. J Am Coll Cardiol
1995;62:18–25.
3. Margonato A, Chierchia S, Cianflone D, et al. Limitations of dipyrid-
amole-echocardiography in effort angina pectoris. Am J Cardiol 1987;
59:225–30.
Overdosing With Prostacyclin
in Primary Pulmonary Hypertension
Rich and McLaughlin (1) reported excessively high rest cardiac
outputs in 12 of 55 patients with primary pulmonary hypertension
(PPH) treated with intravenous prostacyclin, all of whom had
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